HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
01 nov. 2021 00h15 HE
|
HUTCHMED (China) Limited
— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57%...
BlossomHill Therapeutics Closes $71M Series A Financing
03 mars 2021 16h01 HE
|
BlossomHill Therapeutics, Inc.
SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71...
Acute Myeloid Leukemia Therapeutics Market To Reach USD 3.56 Billion By 2027 | Reports And Data
22 juil. 2020 15h04 HE
|
Reports and Data
New York, July 22, 2020 (GLOBE NEWSWIRE) -- Market Size – USD 1.46 Billion in 2019, Market Growth - CAGR of 13.1%, Market Trends – Implementing various growth strategies in therapeutics. New York,...
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
06 janv. 2020 12h05 HE
|
Novartis International AG
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL...
Novartis completes tender offer for all outstanding shares of The Medicines Company
06 janv. 2020 01h00 HE
|
Novartis International AG
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger...
Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
09 déc. 2019 14h45 HE
|
Novartis International AG
Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy adverse...
Global Liver Cancer Treatment Market is Expected to Reach USD 2,186.63 Million by 2025 : Fior Markets
27 août 2019 05h57 HE
|
Fior Markets
New Jersey, NJ, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Rising incidence of liver cancer and growing research activities for developing novel treatments. The global liver cancer treatment market is...
Breast Cancer Therapeutics Market to Exhibit 10.2% CAGR, Increasing R&D Investment to Boost Growth, says Fortune Business Insights
08 juil. 2019 06h15 HE
|
Fortune Business Insights
Pune, July 08, 2019 (GLOBE NEWSWIRE) -- The increasing number of breast cancer cases all over the world is anticipated to boost the global Breast Cancer Therapeutics Market at promising rates, finds...
Lung Cancer Therapeutics Market to reach US$ 48,725.9 Mn by 2026, exhibiting a CAGR of 13.0% | Exclusive Report by Fortune Business Insights
27 juin 2019 08h38 HE
|
Fortune Business Insights
Pune, June 27, 2019 (GLOBE NEWSWIRE) -- Targeted segment is forecast to emerge dominant among various therapies in the Lung Cancer Therapeutics Market, finds Fortune Business Insights in a new...
ASCO and Tempus Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR™) Study
10 janv. 2019 11h00 HE
|
Tempus
ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) -- The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating...